TX-MOUSER-ELECTRONICS
8.6.2023 19:09:27 CEST | Business Wire | Press release
Mouser Electronics Inc., the industry's leading New Product Introduction (NPI) distributor with the widest selection of semiconductors and electronic components™, launches the next installment of their award-winning Empowering Innovation Together (EIT) series highlighting the Matter protocol. With this installment, Mouser brings together global technology experts from the Connectivity Standards Alliance (CSA) and industry-leading manufacturers to explore all aspects of Matter, from market introduction to design specifications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005018/en/
Matter: One protocol for them all. (Graphic: Business Wire)
With its widespread industry support from leading semiconductor manufacturers, including NXP Semiconductors, Silicon Labs, STMicroelectronics, Schneider Electric, Texas Instruments, Infineon Technologies, Nordic Semiconductor and Microchip Technology Inc., Matter promises to revolutionize smart home technology. In this installment, Mouser provides insights and resources to equip engineers and developers with the knowledge needed to design products that harness the power of this new standard. To review the enlightening new series, visit https://www.mouser.com/empowering-innovation/matter-protocol/.
The Matter series features two new episodes of The Tech Between Us podcast, hosted by Mouser's Director of Technical Content Raymond Yin. In episodes part one and two, Yin is joined by Chris LaPré, Chief Technical Officer at the Connectivity Standards Alliance. The pair cover the market's introduction to Matter and explore the types of smart home devices compatible with the new standard. They also dive into the role the CSA plays with Matter and the future focus areas of interest. A third podcast, In Between the Tech, features an interview with Sujata Neidig, Director of Marketing for Wireless Connectivity at NXP Semiconductors. She'll discuss the types of hardware and software behind the Matter protocol, how it impacts manufacturers when it comes to product design and development, as well as what considerations engineers need to make when designing with Matter.
"Matter provides an exciting and innovative way to connect manufacturers, engineers, and consumers through a unified protocol, " says Raymond Yin, Mouser Electronics' Director of Technical Content and host of The Tech Between Us podcast. "I'm thrilled to see and share how companies and individuals are helping create a world of interconnected devices that bring us together by utilizing the Matter standard."
Through educational interviews, infographics, articles, webinars and blogs, this installment explores topics like how to choose a suitable System-on-Module (SoM) for integration, tips for using Matter in product development, tutorials on developing applications based on Matter and more.
Episode co-sponsors include manufacturers Nordic Semiconductor, Schneider Electric, Texas Instruments, NXP Semiconductors, STMicroelectronics, Silicon Labs, Infineon Technologies and Microchip Technology Inc. Mouser's EIT program continues to deliver a variety of insightful content to complement the conversation on The Tech Between Us podcast.
Following the Matter standard, the EIT series will further explore digital therapeutics, environmental sensors, Wi-Fi 7, and industrial machine vision. It will uncover the technical developments needed to keep pace with the evolving world, as well as highlight various new products in the marketplace. Established in 2015, Mouser's Empowering Innovation Together program is one of the industry's most recognized electronic component programs. To learn more, visit https://www.mouser.com/empowering-innovation/ and follow Mouser on Facebook, LinkedIn, Twitter and YouTube.
For more Mouser news, visit https://www.mouser.com/newsroom/.
About Mouser
Mouser Electronics, a Berkshire Hathaway company, is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 6.8 million products from over 1,200 manufacturer brands. Mouser offers 27 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 650,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/.
Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005018/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom